Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities
Translational Research · 2024
DOI: 10.1016/j.trsl.2023.10.004 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Translational Research, 2024. Verfasst von Deborah Lenoci und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Mechanisms Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via GA. Amadeo, 42-20133 Milano, Italy. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Nasopharyngeal Neoplasms, Carcinoma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute.
Abstract (Originalsprache)
Epstein-Barr virus (EBV) related- nasopharyngeal carcinoma (NPC) is a squamous carcinoma of the nasopharyngeal mucosal lining. Endemic areas (EA) are east and Southeast Asia, were NPC was recorded with higher incidence and longer estimated survival than in non-endemic area (NEA) such as Europe, We analyzed the gene expression and microenvironment properties of NPC in both areas to identify molecular subtypes and assess biological and clinical correlates that might explain the differences in incidence and outcome between EA- and NEA-NPCs. Six EA-NPC transcriptomic datasets, including tumor and normal samples, were integrated in a meta-analysis to identify molecular subtypes using a ConsensusClusterPlus bioinformatic approach. Based on the biological/functional characterization of four identified clusters were identified: Cl1, Immune-active; Cl2, defense-response; Cl3, proliferation; Cl4, perineural-interaction/EBV-exhaustion. Kaplan-Meier survival analysis, applied to the single dataset with available disease-free survival indicated Cl3 as the cluster with the worst prognosis (P = 0.0476), confirmed when applying four previously published prognostic signatures. A Cl3 classifier signature was generated and its prognostic performance was confirmed (P = 0.0368) on a validation dataset. Prediction of treatment response suggested better responses to: radiotherapy and immune checkpoint inhibitors immune-active and defense-response clusters; chemotherapy proliferation cluster; cisplatin perineural-interaction/EBV-exhaustion cluster. RNA sequencing for gene expression profiling was performed on 50 NEA-NPC Italian samples. In the NEA cohort, Cl1, Cl2 and Cl3 were represented, while perineural-interaction/EBV-exhaustion was almost absent. The immune/biological characterization and treatment-response prediction analyses of NEA-NPC partially replicated the EA-NPC results. Well characterized EA- and NEA-NPC retrospective and prospective cohorts are needed to validate the obtained results and can help designing future clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Mechanisms Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via GA. Amadeo, 42-20133 Milano, Italy.
- Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy.
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy.
- Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
- Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- Ministero della Salute
Zitieren
APA
Lenoci, D., Resteghini, C., Serafini, M. S., Pistore, F., Canevari, S., Ma, B., Cavalieri, S., Alfieri, S., Trama, A., Licitra, L., & De Cecco, L. (2024). Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities. Translational Research. https://doi.org/10.1016/j.trsl.2023.10.004
Vancouver
Lenoci D, Resteghini C, Serafini MS, Pistore F, Canevari S, Ma B, et al. Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities. Translational Research. 2024. doi:10.1016/j.trsl.2023.10.004
BibTeX
@article{Lenoci2024,
author = {Lenoci, Deborah and Resteghini, Carlo and Serafini, Mara S and Pistore, Federico and Canevari, Silvana and Ma, Brigette and Cavalieri, Stefano and Alfieri, Salvatore and Trama, Annalisa and Licitra, Lisa and De Cecco, Loris},
title = {Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities},
journal = {Translational Research},
year = {2024},
doi = {10.1016/j.trsl.2023.10.004}
}
EUVIMED